inMOLA for Healthcare & Life Sciences
Healthcare marketing is the highest-stakes category in modern marketing: regulated promotions, HCP vs patient targeting, multi-year reputation feedback loops, and zero tolerance for the kind of speed-over-care that other categories accept. inMOLA brings decision intelligence into this environment — used by Massive Bio to rise from 7th to 1st in US oncology while cutting marketing cost 67%.
Healthcare and life sciences marketing leaders carry a burden the rest of marketing does not: every campaign passes through legal and compliance review, every claim has a regulatory footprint, every reputation hit takes years to repair. The data is rich (clinical trial recruitment, HCP outreach, patient education, payer relations) but the constraints are real, and most marketing intelligence tools were built for categories with much lower stakes.
inMOLA was built around continuous evaluation in exactly this kind of environment — where brand health matters more than monthly campaign performance, where compliance posture is non-negotiable, and where the right decision today shows up in revenue eighteen months from now. Most importantly, where what looks like a good number on paper can be wrong in a way that hurts patients.
The four problems we hear most often when we talk to leaders in this category.
Every campaign passes through legal, medical, and regulatory review. The marketing decision cycle is structurally longer than other categories — but the cost of getting it wrong is also structurally higher.
Healthcare professionals respond to peer-reviewed evidence and clinical outcomes. Patients respond to trust, accessibility, and lived experience. Most marketing stacks treat them as one audience.
Brand equity in healthcare compounds over years and erodes over a single incident. By the time the share-of-voice number warns you, the damage is in the press cycle.
A campaign launched today might show its real impact in twelve to eighteen months. Most platforms optimize against this-month metrics — which is exactly the wrong horizon for healthcare.
From the 40+ available, these are the ones we activate first for this category.
Continuous reputation and brand health scoring — share of voice across medical publications, patient communities, and general press. The long-horizon signal healthcare needs.
HCP and patient segmentation with channel-quality scoring. See which acquisition channels feed which cohorts and which cohorts deliver real long-term outcomes.
Compliance and security posture monitoring — audit trails, content compliance reviews, regulatory submission tracking. Built for environments where one slip costs more than the platform.
Healthcare buyers and patients are heavy AI search users — for symptoms, treatments, brand research. Track how your organization appears in ChatGPT, Perplexity, and Gemini answers in your therapeutic areas.
Customer story
From challenger to category leader in US oncology
Massive Bio operates at the frontier of oncology trial matching, where every dollar of marketing spend has to reach patients and persuade institutions. Using inMOLA Core, the team modeled the cost-to-conversion economics of every channel, identified where spend was being wasted, and reallocated budgets toward channels with structural advantages. Inside one working year, Massive Bio rose from 7th to 1st place among seven major companies in brand valuation within the US cancer category — with marketing costs reduced by 67% and target results up 375%.
−67%
Marketing cost
+375%
Target results
7 → 1
US oncology rank
inMOLA reads aggregated marketing performance data, not protected health information. Customer data is encrypted in transit (TLS 1.3) and at rest, with tenant isolation and audit logging. For US healthcare customers handling PHI, the implementation explicitly excludes any PHI sources from ingestion — only marketing performance data is in scope.
inMOLA does not produce marketing content, so it does not directly create regulatory risk. It scores the performance of content your medical, legal, and regulatory teams have already approved — and surfaces strategic decisions that get approved through your standard governance.
Yes. Customer Score and Marketing Mix Score can segment by audience type — HCP, patient, payer, caregiver — when the underlying data sources distinguish them. Most healthcare marketing platforms do; inMOLA reads that segmentation natively.
Built for it. Scoring runs in permanent improvement mode with rolling baselines that match your category's feedback horizon — quarters and years, not weeks. The platform does not assume monthly KPIs are the right comparator.
Probably not yet. inMOLA Core fits established healthcare and life sciences organizations with dedicated marketing leadership and active brand-building. Clinical-stage biotechs typically fit inMOLA Spark better, which scales down to SMB budgets.
Yes. Every integration is explicit and reviewable. Healthcare implementations typically scope tightly — marketing performance data only, no patient records, no clinical data — and that scope is auditable inside the platform.
We will walk through a healthcare-scoped implementation — what we read, what we do not read, how compliance and continuous evaluation work in practice. Founder-led, not sales-led.